BC Innovations | Dec 19, 2018
Distillery Therapeutics

Hematology

INDICATION: Bleeding In vitro and human plasma studies identified a peptide-based plasmin inhibitor that could help treat bleeding. Chemical synthesis and in vitro testing of analogs of a sunflower cyclic peptide serine protease inhibitor in...
BC Extra | Sep 25, 2018
Preclinical News

Ionis, Rockefeller team find peripheral blood target for Alzheimer's

Ionis Pharmaceutics Inc. (NASDAQ:IONS) and The Rockefeller University found blood plasmin drives Alzheimer's disease progression and immune responses in the brain, shedding light on neuroinflammation's role in AD. The team suggested antisense oligonucleotide depletion of...
BC Week In Review | Dec 15, 2017
Clinical News

ThromboGenics stops diabetic retinopathy trial due to slow enrollment

ThromboGenics N.V. (Euronext:THR) discontinued enrollment in the Phase II CIRCLE trial evaluating ocriplasmin (THR-409) to treat non-proliferative diabetic retinopathy (NPDR) due to slow recruitment rate, which ThromboGenics CEO Patrik De Haes attributed to "patients being...
BC Week In Review | Jan 12, 2017
Clinical News

Jetrea: Ph II CIRCLE amended

ThromboGenics amended the double-blind, sham-controlled, international Phase II CIRCLE trial of Jetrea to expand the enrollment criteria and decrease enrollment to about 115 patients from 230. CIRCLE will now enroll patients with moderate to very...
BC Week In Review | Feb 15, 2016
Clinical News

Jetrea ocriplasmin: Phase II started

ThromboGenics began the double-blind, placebo-controlled, international Phase II CIRCLE trial to evaluate up to 3 intravitreal injections of 0.0625 and 0.125 mg ocriplasmin in 230 patients with non-proliferative diabetic retinopathy. Ocriplasmin is approved as Jetrea...
BC Week In Review | Apr 6, 2015
Clinical News

Jetrea ocriplasmin: Phase II data

Top-line data from the double-blind, U.S. Phase II OASIS trial in about 220 patients with symptomatic VMA showed that a single 125 ug intravitreal injection of Jetrea met the primary endpoint of a greater proportion...
BioCentury | Mar 30, 2015
Emerging Company Profile

Effusion dissolution

Lung Therapeutics Inc. is developing therapies that prevent or resolve fibrosis to treat Orphan lung diseases. Lead product LTI-01 is a formulation of a fibrinolytic enzyme in preclinical development to prevent and clear loculated pleural...
BC Week In Review | Feb 16, 2015
Clinical News

Jetrea ocriplasmin regulatory update

ThromboGenics said Argentina and Israel approved Jetrea ocriplasmin to treat vitreomacular traction (VMT), including when associated with a macular hole diameter of =400 um. The Alcon Inc. ophthalmic unit of Novartis AG (NYSE:NVS; SIX:NOVN, Basel,...
BC Week In Review | Oct 20, 2014
Clinical News

Jetrea ocriplasmin regulatory update

ThromboGenics said Australia's Therapeutic Goods Administration ( TGA ) approved Jetrea ocriplasmin to treat vitreomacular traction (VMT), including when associated with macular hole of diameter <=400 Ug. The Alcon Inc. ophthalmic unit of Novartis AG (NYSE:NVS; SIX:NOVN,...
BC Week In Review | Sep 15, 2014
Clinical News

Jetrea ocriplasmin regulatory update

ThromboGenics said South Korea approved Jetrea ocriplasmin to treat vitreomacular adhesion (VMA), including when associated with macular hole diameter of <=400 microns. The company said South Korea is the fourth country in Asia to approve...
Items per page:
1 - 10 of 151